Stoke Therapeutics (STOK) director Smith received 17,786 units
Stocks in this Quantisnow insightHealth Care
Insider transactions reported
Julie Smith (director at Stoke Therapeutics Inc., STOK) reported that they received 17,786 units on Jun 3, 2026.
- Reporting person
- Smith Julie
Options and other derivatives
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Jun 3, 2026 | Grant or award (A) | Director Stock Option (Right to Buy)On 17,786 Common Stock1 | +17,786 | - | - | 17,786 direct |
Holdings before and after
- Director Stock Option (Right to Buy): 0 to 17,786 direct
Footnotes from the filing
- 1. The option shall vest in full on the earlier of: (i) June 3, 2027 or (ii) the date of the issuer's next annual meeting of its stockholders, subject to the reporting person's continued service to the issuer on the vesting date.
Transaction codes in this filing
- Grant or award:
- Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.
FAQ
What did Smith report in this STOK Form 4?
Julie Smith (director at Stoke Therapeutics Inc., STOK) reported that they received 17,786 units on Jun 3, 2026.
What does transaction code A mean on an SEC Form 4?
Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.
Historical context for STOK
Across the 17 sessions after earlier STOK headlines, the stock closed higher 7 times and lower 10 times, with a median move of 3.2% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | STOK | SPY |
|---|---|---|---|
| May 19, 2026 | Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) | +3.2% | -0.7% |
| Apr 17, 2026 | Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) | +5.5% | +1.2% |
| Mar 18, 2026 | Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) | -5.6% | -1.4% |
| Feb 24, 2026 | Wolfe Research initiated coverage on Stoke Therapeutics with a new price target | -2.0% | +0.7% |
| Feb 19, 2026 | Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) | +10.9% | -0.3% |
| Feb 11, 2026 | Stoke Therapeutics Announces First Patient Dosed in Phase 1 Study of STK-002, a Potential Disease-Modifying Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA) | -0.7% | -0.0% |
Earlier insider filings at STOK
Keep researching STOK
- STOK insider tradesEvery buy and sale reported by Stoke Therapeutics Inc. officers, directors and large holders.
- What is Form 4?The SEC filing that reports a change in an insider's holdings, such as a purchase, sale, option exercise or grant, generally within two business days.
- Form 4 explainedForm 4 is the SEC filing that discloses when officers, directors and 10% owners buy or sell company stock, due within 2 business days. Learn every key field and code.
- Insider trading trackerThe latest insider buys and sales across every stock.
- STOK earnings historyPast Stoke Therapeutics Inc. earnings releases, newest first.
- STOK financial statementsRevenue, profit, cash flow and balance sheet from Stoke Therapeutics Inc.'s SEC filings.
Quantisnow market dataNASDAQ
STOK
Stoke Therapeutics Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2019
Get push alerts for STOK
Full STOK profile on Quantisnow Follow STOK and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time